Christelle Huguet
President chez ALBIREO PHARMA, INC.
Profil
Christelle Huguet is currently the Co-Chief Executive Officer at Ipsen Innovation SASU, the Executive VP and Head of Research & Development at Ipsen SA, and the President at Albireo Pharma, Inc. Previously, she held the position of President at Epizyme, Inc. She obtained a doctorate degree from Pasteur Institute.
Postes actifs de Christelle Huguet
| Sociétés | Poste | Début |
|---|---|---|
| ALBIREO PHARMA, INC. | President | 02/03/2023 |
| IPSEN | Chief Tech/Sci/R&D Officer | 22/09/2023 |
Ipsen Innovation SASU
 Ipsen Innovation SASU Engineering & ConstructionIndustrial Services Part of Ipsen SA, Ipsen Innovation SASU is a French biopharmaceutical company that focuses on improving patients' lives through research and innovation in oncology, rare disease, and neuroscience. Ipsen Innovation is based in Les Ulis, France. The private company aims to prolong patients' lives, improve health outcomes, and create a positive impact for patients and society. The company was founded in 1996, and the CEOs are Christelle Huguet and Jose Camara Ferrer. | Chief Executive Officer | 08/07/2021 |
Anciens postes connus de Christelle Huguet
| Sociétés | Poste | Fin |
|---|---|---|
| EPIZYME, INC. | President | - |
Formation de Christelle Huguet
| Pasteur Institute | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| IPSEN | Health Technology |
| Entreprise privées | 3 |
|---|---|
Epizyme, Inc.
 Epizyme, Inc. BiotechnologyHealth Technology Epizyme, Inc. is a clinical-stage biopharmaceutical company. The firm engages in the discovery, development, and commercialization of novel epigenetic medicines for cancer and other diseases. Its product pipeline is lead by, tazemetostat which targets Non-Hodgkin Lymphoma, molecularly defined solid tumors, non-small-cell lung carcinoma, molecularly targeted tumors, and ovarian cancer. The firm also develops pinometostat for genetically defined acute leukemia, and EZM8266 for sickle cell disease. The company was founded by Robert Horvitz and Zhang Yi on November 1, 2007 and is headquartered in Cambridge, MA. | Health Technology |
Albireo Pharma, Inc.
 Albireo Pharma, Inc. Pharmaceuticals: MajorHealth Technology Albireo Pharma, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of novel bile acid modulators for the treatment of orphan pediatric liver diseases and gastrointestinal disorders. Its pipeline products include Odevixibat, A3384, and Elobixibat. The company was founded by Jan Peter Mattsson and Per-Göran Gillberg on December 8, 2003 and is headquartered in Boston, MA. | Health Technology |
Ipsen Innovation SASU
Ipsen Innovation SASU Engineering & ConstructionIndustrial Services Part of Ipsen SA, Ipsen Innovation SASU is a French biopharmaceutical company that focuses on improving patients' lives through research and innovation in oncology, rare disease, and neuroscience. Ipsen Innovation is based in Les Ulis, France. The private company aims to prolong patients' lives, improve health outcomes, and create a positive impact for patients and society. The company was founded in 1996, and the CEOs are Christelle Huguet and Jose Camara Ferrer. | Industrial Services |
